1. Pomerantz LLP is investigating claims against Soleno Therapeutics, Inc. 2. Investors may have suffered due to alleged securities fraud. 3. Scorpion Capital's report claims Soleno's product is overpriced and unsafe. 4. Soleno's stock price dropped 7.41% following the report's publication. 5. Investors are urged to contact Pomerantz for more details.
The investigation suggests serious concerns regarding management's actions leading to potential stock devaluation. Past incidents show significant drops in stocks under similar allegations, reinforcing investor hesitance.
The ongoing legal investigation has a high likelihood of influencing investor perception and stock value immediately. This is compounded by significant price drops already observed.
The immediate impact of the class-action investigation could negatively affect stock prices in the near term, as seen in past cases involving securities fraud disclosures.
NEW YORK, Aug. 25, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ:SLNO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
The investigation concerns whether Soleno and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On August 15, 2025, Scorpion Capital ("Scorpion") published a report that described Soleno's only product, Vykat XR, as overpriced and potentially unsafe for children.
Following publication of the Scorpion report, Soleno's stock price fell $5.73 per share, or 7.41%, to close at $71.63 per share on August 15, 2025.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Danielle Peyton
Pomerantz LLP
dpeyton@pomlaw.com
646-581-9980 ext. 7980
View original content to download multimedia:https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-soleno-therapeutics-inc---slno-302538148.html
SOURCE Pomerantz LLP